China Pharma Eyes Brighter SE Asia Markets Amid US Entry Shadows

Junshi is the latest Chinese company to announce plans to expand into Southeast Asia, where its compatriot firms are also eyeing large market potential and are set to benefit from less stringent reviews of China-only clinical data due to fewer questions around ethnic differences versus the US.

China and Southeast Asia
Chinese pharma companies explore new opportunities to cash in on novel drugs in Southeast Asia • Source: Shutterstock

Chinese pharma companies are now taking some of their principal products to the smaller global markets of Southeast Asia, which a number are targeting in an expansion push.

Hong Kong- and Shanghai-listed Shanghai Junshi Biosciences Co., Ltd. joined the race on 28 March, partnering with Rxilient Biotech Pte. Ltd

More from Focus On Asia

More from Scrip